At the moment, there are six CAR-T therapies with FDA approval summarized in Table 1.
Table 1. FDA Approved CAR-T Therapies.9| Brand Name | Generic Name | Targeted Tumor Antigen | Targeted Blood Cancer |
| Kymriah | Tisagenlecleucel | CD19 | Leukemia (ALL) & Lymphoma (NHL) |
| Yescata | Axicabtagene ciloleucel | CD19 | Follicular lymphoma & Lymphoma (NHL) |
| Brexucabtagene autoleucel | CD19 | Mantel cell lymphoma & Leukemia (ALL) |
| Tecartus | Lisocabtagene maraleucel | CD19 | Lymphoma (NHL) |
| Breyzani | Idecabtagene autoleucel | BCMA | Multiple myeloma |
| Abecma | Ciltacagene autoleucel | BCMA | Multiple myeloma |
ALL = acute lymphocytic leukemia; NHL = non-hodgkin lymphoma
As shown above, three types of blood cancers are targeted: leukemia, lymphoma, and multiple myeloma. The same cancer antigen, CD19, is the target for leukemia and lymphoma, but a different cancer antigen, BCMA, is the target for multiple myeloma.
